July 29, 2026 Merck & Co. Announces Fourth-Quarter 2026 Dividend Merck & Co. has declared a quarterly dividend of $0.85 per share for Q4 2026, highlighting its strong financial position and dedication to shareholder value. This move demonstrates Merck's confidence in its operations and future growth prospects within the pharmaceutical industry.
July 24, 2026 Merck's Innovative Strategy for HIV Prevention: Early Access Plans for Alimatravir Merck has introduced plans for early access to alimatravir, a once-monthly oral pill for HIV prevention, targeting low- and middle-income countries. This initiative includes generic licensing agreements and community engagement to ensure broad access and support local manufacturing efforts.
July 16, 2026 Merck & Co Inc. Launches LIPFENDRA®: A Game-Changer in Cholesterol Management Merck & Co Inc. has launched LIPFENDRA®, the first oral PCSK9 inhibitor approved by the FDA for hypercholesterolemia, showing up to 60% LDL-C reduction in trials. This groundbreaking treatment offers a new option for managing high cholesterol, crucial for cardiovascular health.
July 15, 2026 Merck & Co Inc. Poised to Showcase Groundbreaking HIV Research at AIDS 2026 Merck & Co Inc. is set to unveil new HIV treatment data at the AIDS 2026 conference in Rio de Janeiro, focusing on innovative oral treatments. Their presentations will highlight pivotal studies on islatravir and other regimens, emphasizing the company's commitment to advancing HIV care.
July 15, 2026 Merck & Co Inc. Reports Promising Results for KEYTRUDA® in Advanced Endometrial Cancer Merck's KEYTRUDA® has shown significant improvement in progression-free survival for advanced endometrial cancer patients in the KEYNOTE-C93 trial, making it the first PD-1 inhibitor to achieve such results. The findings pave the way for potentially chemo-free treatment options, with further evaluations ongoing.
July 10, 2026 FDA Approves KEYTRUDA® and KEYTRUDA QLEX™ for Muscle-Invasive Bladder Cancer The FDA has approved KEYTRUDA and KEYTRUDA QLEX for treating muscle-invasive bladder cancer, marking a significant advancement in cancer therapy. These new treatments improve survival outcomes and offer hope to patients, especially those ineligible for traditional chemotherapy.
July 01, 2026 Merck & Co. to Host Q2 2026 Earnings Call: Key Insights Awaited Merck & Co. will host its Q2 2026 earnings call on August 4, providing vital insights into the company's financial performance and strategic direction. Participants can access the call via webcast or phone and are encouraged to review forward-looking statements regarding industry risks.
June 29, 2026 Merck & Co Inc. Expands HIV Treatment Access with New Agreement Merck & Co has partnered with the ADAP Crisis Task Force to improve access to its new HIV treatment, IDVYNSO. This initiative aims to support individuals living with HIV, especially those underserved, while promoting innovative care options.
June 25, 2026 Merck & Co. Inc. Achieves Landmark FDA Approvals for KEYTRUDA® and KEYTRUDA QLEX™ in Advanced Triple-Negative Breast Cancer Merck & Co. has received FDA approval for KEYTRUDA and KEYTRUDA QLEX as groundbreaking first-line treatments for advanced triple-negative breast cancer. The combination with Trodelvy shows significant improvements in patient outcomes, offering new hope in oncology.
June 24, 2026 Merck Secures Landmark Approval for KEYTRUDA® and Padcev® Combination Therapy in EU Merck has received EU approval for KEYTRUDA and Padcev as a combination therapy for muscle-invasive bladder cancer, marking a significant advancement in treatment options. The therapy shows promising efficacy, significantly improving survival rates compared to traditional surgery alone, addressing a crucial unmet need.
June 22, 2026 Merck & Co Inc. Reports Positive Phase 3 Results for Tulisokibart in Ulcerative Colitis Treatment Merck & Co Inc. announced positive results from its Phase 3 study of Tulisokibart for ulcerative colitis, achieving key endpoints with no safety concerns. This breakthrough may redefine treatment options for patients with this chronic condition.
June 18, 2026 Merck & Co. Expands CAPVAXIVE® Indication to Protect High-Risk Youth Against Pneumococcal Disease Merck & Co. has received FDA approval to expand the use of its CAPVAXIVE® vaccine for high-risk children and adolescents aged 2-17. This 21-valent vaccine aims to protect against pneumococcal disease, addressing a critical need for immunization in vulnerable populations with chronic conditions.
June 17, 2026 Merck Animal Health Highlights Challenges in Treating Allergic Skin Disease in Dogs Merck Animal Health's survey reveals the challenges in diagnosing and treating allergic skin disease in dogs, affecting both pet owners and veterinarians. Emotional burdens and treatment dissatisfaction highlight the need for improved communication and innovative solutions in veterinary care.
June 12, 2026 Merck & Co Inc. Secures FDA Approval for Innovative Cancer Treatments Merck & Co Inc. received FDA approval for KEYTRUDA and WELIREG to treat adult patients with clear cell renal cell carcinoma. The combination therapy showed a 28% reduction in disease recurrence risk in clinical trials, marking a significant advancement in cancer treatment.
June 11, 2026 Merck Animal Health Expands Its Reach with TARGAN Acquisition Merck Animal Health has announced its acquisition of TARGAN, enhancing its capabilities in the poultry sector with innovative biodevice solutions, including the WingScan™ system. This strategic move is poised to improve operational efficiency and animal health outcomes in commercial hatcheries.
June 08, 2026 Merck & Co Inc. and Gilead Sciences Discontinue Phase 3 Study on Combination Therapy for Lung Cancer Merck & Gilead have discontinued their Phase 3 study on a combination therapy for metastatic non-small cell lung cancer due to insufficient statistical significance in survival rates. Despite this setback, both companies remain committed to advancing cancer research and treatments.
June 02, 2026 Merck to Showcase Innovations at Goldman Sachs Healthcare Conference Merck & Co. will present at the Goldman Sachs Healthcare Conference on June 9, featuring insights from CEO Robert M. Davis and Dr. Dean Y. Li. The event emphasizes Merck's commitment to innovation, diversity, and sustainability in healthcare.
May 29, 2026 Merck & Co Inc. Secures Breakthrough Therapy Designation for Calderasib in Lung Cancer Treatment Merck & Co has achieved FDA Breakthrough Therapy designation for calderasib, a KRAS G12C inhibitor aimed at treating metastatic non-small cell lung cancer. This recognition is based on promising Phase 1 trial results and underscores the urgent need for targeted therapies in lung cancer treatment.
May 28, 2026 Merck & Co Inc. to Showcase Oncology Innovations at Jefferies Global Healthcare Conference Merck & Co. Inc. will present its oncology advancements at the Jefferies Global Healthcare Conference on June 4, 2026. Dr. Marjorie Green will lead discussions on innovative cancer treatments and Merck's commitment to research and development.
May 26, 2026 Merck & Co. Declares Third-Quarter Dividend for 2026 Merck & Co. has declared a quarterly dividend of $0.85 per share, set to be paid on July 8, 2026. This decision reflects the company's strong financial health and commitment to shareholders, amidst potential industry challenges. Merck remains focused on research and development to address global health needs.
May 22, 2026 Merck Advances Cancer Treatment with Positive EU CHMP Opinion for KEYTRUDA and Padcev Combination Merck's recent CHMP recommendation for KEYTRUDA and Padcev offers new hope for bladder cancer patients ineligible for cisplatin treatment. Clinical trials show significant improvements in survival rates, paving the way for potential market approval in Europe.
May 07, 2026 Merck & Co. Inc. Pioneers New Frontiers in Cardiovascular Treatment with Enlicitide Decanoate Merck & Co. has published groundbreaking research on enlicitide decanoate, an innovative oral PCSK9 inhibitor aimed at lowering LDL cholesterol. This new treatment could revolutionize cardiovascular therapy and improve patient access to essential medications. With a focus on sustainable biocatalysis, Merck is leading the charge against cardiovascular disease.
May 05, 2026 Merck & Co. Inc. Finalizes Acquisition of Terns Pharmaceuticals On May 5, 2026, Merck completed the acquisition of Terns Pharmaceuticals, focusing on advancing treatments for chronic myeloid leukemia. This strategic move centers on TERN-701, an investigational therapy with Breakthrough Therapy Designation from the FDA, aimed at improving patient outcomes.
May 04, 2026 Merck & Co., Inc. Reports Mixed Q1 2026 Results Amid Major Acquisitions and Pricing Pressures Merck & Co. announced its Q1 2026 results, featuring a 5% increase in sales to $16.3 billion, but a net loss of $4.24 billion. The company faces challenges from pricing pressures and high R&D costs, while strategic acquisitions aim to enhance its future pipeline.
April 30, 2026 Merck & Co. Reports First-Quarter 2026 Financial Results: A New Chapter Unfolds Merck & Co. reported a 5% increase in sales for Q1 2026, totaling $16.286 billion, but faced a GAAP net loss of $4.240 billion due to acquisition charges. The company is diversifying its portfolio and has made significant advancements in its drug pipeline, positioning itself for future growth.
April 24, 2026 Merck & Co. Inc. Moves Forward with Terns Pharmaceuticals Acquisition Merck & Co. has successfully completed the HSR waiting period for its acquisition of Terns Pharmaceuticals, enhancing its biopharmaceutical portfolio. The cash tender offer, set at $53 per share, requires over 50% shareholder participation to proceed. This strategic move is expected to bolster Merck's competitive edge in the industry.
April 21, 2026 FDA Approves Merck’s New Once-Daily HIV Treatment IDVYNSO™ Merck's IDVYNSO™ has received FDA approval as a once-daily, two-drug regimen for HIV-1 treatment, aimed at adults with virologic suppression. This new therapy, combining doravirine and islatravir, offers a tenofovir-free option and supports the evolving health needs of aging patients.
April 21, 2026 Merck & Co Inc. and Eisai Update on Phase 3 LITESPARK-012 Trial Results Merck & Co Inc. and Eisai's Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma failed to meet its primary endpoints, reaffirming the efficacy of the established KEYTRUDA plus LENVIMA regimen. Despite the disappointing results, the findings will influence future treatment approaches and ongoing trials.
April 20, 2026 FDA Grants Priority Review for Merck's KEYTRUDA and KEYTRUDA QLEX Combination Therapy The FDA has granted priority review for Merck's KEYTRUDA and KEYTRUDA QLEX, aiming to enhance treatment options for muscle-invasive bladder cancer. This decision is based on promising data from the KEYNOTE-B15 trial, and if approved, it could significantly improve outcomes for patients facing limited treatment alternatives.
April 17, 2026 Merck's ENFLONSIA™ Receives European Approval to Combat RSV in Infants Merck's ENFLONSIA has received European approval to prevent RSV in infants, a significant step in pediatric health. Supported by clinical trials, this long-acting monoclonal antibody offers effective protection during RSV season, potentially reducing hospitalizations and severe cases.
April 13, 2026 Merck and Daiichi Sankyo's Ifinatamab Deruxtecan Receives Priority Review from FDA Merck and Daiichi Sankyo's ifinatamab deruxtecan has received FDA Priority Review for treating extensive-stage small cell lung cancer. This investigational therapy targets the B7-H3 protein and is supported by promising clinical trial results. The FDA's decision is expected on October 10, 2026.
April 07, 2026 Merck Initiates Tender Offer for Terns Pharmaceuticals Merck & Co. has announced a tender offer to acquire Terns Pharmaceuticals for $53.00 per share, following a definitive agreement. The offer is set to close on May 4, 2026, pending certain conditions, as Merck aims to boost its biopharmaceutical capabilities.
April 02, 2026 Merck & Co Inc. Secures European Approval for KEYTRUDA® in Ovarian Cancer Treatment Merck & Co Inc. has received European approval for KEYTRUDA® in treating platinum-resistant recurrent ovarian cancer, marking a significant advancement. This treatment, proven effective in clinical trials, addresses a crucial unmet need for patients resistant to conventional therapies.
April 02, 2026 Merck & Co Inc. Launches Pivotal Trial for Groundbreaking Eye Therapy Merck & Co Inc. has launched the MALBEC trial for MK-8748, a bispecific antibody aimed at treating neovascular age-related macular degeneration. The study seeks to evaluate its effectiveness compared to existing therapies, potentially reshaping treatment for vision loss in older adults.
April 01, 2026 Merck & Co Inc. to Host First-Quarter 2026 Sales and Earnings Conference Call Merck & Co Inc. will hold its first-quarter 2026 earnings call on April 30, focusing on financial results and market insights. The call is accessible to all stakeholders, promising valuable updates on the company's strategic direction and ongoing innovations.
March 30, 2026 Merck & Co Inc. Reports Promising Results for Enlicitide Decanoate in Cardiovascular Study Merck & Co Inc. reports that its investigational oral PCSK9 inhibitor, enlicitide decanoate, significantly reduces LDL-C levels in a Phase 3 trial. With a favorable safety profile, the drug demonstrates potential to improve cardiovascular health outcomes by effectively managing cholesterol levels.
March 29, 2026 Merck & Co. Announces Positive Phase 2 Data for WINREVAIR™ in Heart Failure Treatment Merck & Co. announced positive results from its Phase 2 CADENCE study for WINREVAIR, showing significant reductions in pulmonary vascular resistance in CpcPH-HFpEF patients. The promising findings support the need for effective treatments and set the stage for upcoming Phase 3 trials.
March 25, 2026 Merck to Acquire Terns Pharmaceuticals: A Strategic Move in Hematology Merck & Co is set to acquire Terns Pharmaceuticals for approximately $6.7 billion, focusing on TERN-701, an innovative treatment for chronic myeloid leukemia. This strategic move enhances Merck's presence in the hematology sector and promises to deliver effective therapies to patients in need.
March 18, 2026 Merck & Co. Inc. Announces FDA Approval for BRAVECTO® QUANTUM: A Game-Changer in Canine Tick Protection Merck Animal Health has announced FDA approval for BRAVECTO QUANTUM, enhancing tick protection for dogs with a year-long solution. The new treatment addresses emerging tick species and streamlines care for pet owners and veterinarians.
March 17, 2026 Merck & Co Inc. Reaffirms Long-Term Efficacy of HPV Vaccines at EUROGIN Congress Merck & Co Inc. will present new data at the EUROGIN Congress 2026, showcasing the long-term effectiveness of its HPV vaccines GARDASIL®9 and GARDASIL®. The findings emphasize the importance of vaccination in preventing HPV-related cancers, with efficacy lasting up to 18 years.
March 16, 2026 Merck Announces Promising Data from Cardio-Pulmonary Pipeline Ahead of ACC.26 Merck is set to present innovative clinical data from its cardio-pulmonary pipeline at ACC.26, including promising results from trials on enlicitide and sotatercept. These advancements aim to address hypercholesterolemia and CpcPH-HFpEF, highlighting Merck's dedication to improving patient outcomes.
February 27, 2026 Merck & Co. Inc. Achieves Significant Advances in Ovarian Cancer Treatment with KEYTRUDA® Merck's KEYNOTE-B96 trial reveals that KEYTRUDA® combined with paclitaxel significantly enhances survival for patients with platinum-resistant ovarian cancer. The European Medicines Agency has endorsed this promising therapy, marking a major advancement in treatment options.
February 27, 2026 Merck & Co. Unveils Promising Data for KEYTRUDA® and Padcev® in Bladder Cancer Treatment Merck's recent findings at the ASCO GU Cancers Symposium reveal that combining KEYTRUDA and Padcev significantly improves event-free survival and overall survival rates in muscle-invasive bladder cancer patients. The results suggest a potential shift in treatment standards for cisplatin-eligible patients.
February 25, 2026 Merck & Co. Inc. Announces FDA Approval of NUMELVI™ for Dogs: A Game-Changer in Veterinary Medicine Merck Animal Health's NUMELVI™ has received FDA approval as the first second-generation JAK inhibitor for treating allergic dermatitis in dogs. Set for release in spring 2026, this innovative treatment promises rapid relief from itching and a significant improvement in the quality of life for affected pets.
February 25, 2026 Merck & Co Inc. Unveils Promising Phase 3 Data for Doravirine/Islatravir Regimen at CROI 2026 Merck & Co Inc. revealed promising Phase 3 trial results for doravirine/islatravir (DOR/ISL) at CROI 2026, showing high efficacy and safety for HIV-1 treatment. This regimen may reshape HIV therapy, targeting diverse patient needs and marking a significant step in the company's 40-year legacy in HIV research.
February 24, 2026 Merck & Co. to Engage with Investors at TD Cowen 46th Annual Health Care Conference Merck & Co. will participate in the TD Cowen 46th Annual Health Care Conference, featuring insights from key executives on financial strategies and research initiatives. The event highlights Merck's commitment to transparency and innovation in the biopharmaceutical sector.
February 24, 2026 Merck & Co., Inc. Reports Steady Growth in 2025 Annual Report Merck & Co. reported a modest 1% revenue growth in its 2025 Annual Report, driven by advancements in oncology and animal health. Despite challenges in international markets and declining vaccine sales, the company remains focused on innovation and shareholder value.
February 23, 2026 Merck & Co. Inc. Restructures Human Health Organization for Future Growth Merck & Co. Inc. has restructured its Human Health organization to create specialized business units in oncology and specialty diseases. Key leadership appointments aim to strengthen its portfolio execution and innovation strategy, positioning the company for future growth in the competitive pharmaceutical market.
February 19, 2026 Merck & Co Inc. Reports Promising Data on ENFLONSIA™ for High-Risk Infants Merck & Co's ENFLONSIA™ shows promising results for high-risk infants in the Phase 3 SMART trial, maintaining a consistent safety profile and efficacy across two RSV seasons. The findings could lead to expanded use in preventing severe RSV disease in vulnerable children.
February 18, 2026 Merck & Mayo Clinic Forge Groundbreaking AI-Enabled Drug Discovery Partnership Merck & Co. and Mayo Clinic have partnered to use AI and advanced analytics in drug discovery, focusing on conditions like Inflammatory Bowel Disease and Multiple Sclerosis. This collaboration aims to accelerate the development of personalized therapies, leveraging extensive clinical data and innovative technology to improve patient outcomes.
February 12, 2026 Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium Merck presents significant advancements in bladder and kidney cancer treatments at the 2026 ASCO GU Symposium, highlighting key trials like KEYNOTE-B15/EV-304 and LITESPARK-022. These findings aim to improve patient outcomes and treatment standards in oncology.
February 11, 2026 Merck & Co. Inc. Announces FDA Approval for KEYTRUDA® and KEYTRUDA QLEX™ in Ovarian Cancer Treatment Merck & Co. has announced FDA approval for KEYTRUDA and KEYTRUDA QLEX to treat platinum-resistant ovarian cancer, improving survival rates. The approval is based on positive results from the Phase 3 KEYNOTE-B96 trial, representing a vital advancement in cancer treatment.
February 03, 2026 Merck & Co., Inc. Reports Fourth-Quarter and Full-Year 2025 Financial Results Merck & Co., Inc. reported strong financial results for 2025, with total sales reaching $65 billion. Despite a decline in net income, the company showed resilience through innovative product performance and a promising pipeline. Looking ahead, Merck anticipates continued growth in 2026.
January 27, 2026 Merck & Co. Inc. Declares Quarterly Dividend for Second Quarter 2026 Merck & Co. Inc. has declared a quarterly dividend of $0.85 per share for Q2 2026, showcasing its strong financial position and dedication to shareholder value. The payment is scheduled for April 7, 2026, affirming the company's commitment to advancing global health through innovative solutions.
January 07, 2026 Merck & Co. Launches KANDLELIT-007 Trial for Advanced Lung Cancer Treatment Merck & Co. has initiated the KANDLELIT-007 trial to assess the efficacy of calderasib combined with KEYTRUDA QLEX in patients with advanced lung cancer. This groundbreaking study aims to improve outcomes for those with the KRAS G12C mutation, highlighting the need for innovative treatments in lung cancer care.
January 07, 2026 Merck & Co. Completes Acquisition of Cidara Therapeutics: A Strategic Move in the Respiratory Portfolio Merck & Co. has completed its acquisition of Cidara Therapeutics, paying $221.50 per share to enhance its respiratory portfolio. This move centers on CD388, a promising antiviral candidate for preventing influenza complications, reflecting Merck's commitment to public health innovation.
January 07, 2026 Merck & Co Inc. to Host Fourth-Quarter and Full-Year 2025 Earnings Call Merck & Co Inc. will hold its fourth-quarter and full-year 2025 earnings call on February 3, 2026. The call aims to provide insights into the company's financial performance and strategic direction amid a changing pharmaceutical landscape.
January 05, 2026 Merck & Co Inc. Set to Showcase Innovations at the 44th Annual J.P. Morgan Healthcare Conference Merck & Co Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, featuring key executives discussing the company's innovations and future strategies. The event highlights Merck's commitment to transparency with live web access for stakeholders.
December 19, 2025 Merck & Co Inc. Announces Landmark Agreement to Enhance Drug Accessibility and Affordability Merck & Co Inc. has announced a historic agreement with the U.S. government aimed at making prescription medications more affordable and accessible. This initiative includes a direct-to-patient program offering significant price reductions on key drugs and plans for substantial investment in U.S. manufacturing.
December 17, 2025 Merck & Co. Announces Groundbreaking Results in Bladder Cancer Treatment Merck & Co. announced positive results from its KEYNOTE-B15 trial, showcasing improved survival outcomes for muscle-invasive bladder cancer patients using KEYTRUDA and Padcev. The safety profile remained consistent, and the company is committed to advancing cancer treatments further.
December 12, 2025 Merck Receives Positive EU CHMP Opinion for WINREVAIR™ Expansion Merck's WINREVAIR™ may expand treatment for pulmonary arterial hypertension (PAH) to include more patients, pending European Commission approval. Supported by promising Phase 3 ZENITH study data, this therapy shows significant efficacy in reducing morbidity and mortality. Its broader use could transform care for thousands affected by PAH in Europe.
December 04, 2025 Merck & Co., Inc. Announces Conditional FDA Approval of EXZOLT™ CATTLE-CA1 Merck Animal Health has received conditional FDA approval for EXZOLT™ CATTLE-CA1, a new topical solution for treating New World screwworm in cattle. This innovative product aims to protect cattle producers from significant economic losses and is available in early 2026.
December 01, 2025 Merck & Co Inc. Unveils Promising Alzheimer's Candidates at CTAD 2025 Merck & Co Inc. presented promising data for Alzheimer's candidates MK-2214 and MK-1167 at CTAD 2025, focusing on innovative treatments to combat the disease. With Fast Track Designation from the FDA, MK-2214 targets tau protein accumulation, while MK-1167 aims to enhance cognitive function. These developments mark significant strides in Alzheimer's research and therapy.
November 26, 2025 Merck & Co Inc. to Engage in Fireside Chat at Citi 2025 Global Healthcare Conference Merck & Co will participate in the Citi 2025 Global Healthcare Conference on December 3, featuring key executives discussing their innovative strategies and commitment to healthcare. The event emphasizes Merck's dedication to advancing medical science and corporate responsibility.
November 26, 2025 Merck & Co. Inc. Prepares to Showcase Innovations at Evercore ISI HealthCONx Conference Merck & Co. will participate in the Evercore ISI HealthCONx Conference on December 2, 2025, featuring key executives discussing the company's innovations and strategy. This event highlights Merck's commitment to transparency and engagement with stakeholders while addressing future challenges in the biopharmaceutical landscape.
November 24, 2025 Merck & Co Inc. Prepares for ASH 2025 Annual Meeting: A Focus on Hematology Innovations Merck & Co Inc. is set to present over 20 abstracts at ASH 2025, highlighting its commitment to hematology research. Key investigational therapies include MK-1045, Bomedemstat, and Nemtabrutinib, aimed at improving outcomes for patients with hematologic malignancies.
November 19, 2025 Merck Announces Promising Results for New HIV Treatment Regimen Merck's Phase 3 trial results for the doravirine/islatravir (DOR/ISL) regimen show it is as effective and safe as the three-drug regimen for HIV-1. The company plans to pursue regulatory submissions for this promising new treatment option.
November 19, 2025 Merck & Co Inc. Receives European Approval for KEYTRUDA® SC Merck & Co Inc. has received European Commission approval for KEYTRUDA SC, a subcutaneous cancer treatment that offers faster administration and similar efficacy to intravenous options. This innovative therapy enhances patient experience and is set to transform cancer treatment in Europe.
November 18, 2025 Merck & Co. Inc. Declares First-Quarter 2026 Dividend Merck & Co. Inc. has declared a quarterly dividend of $0.85 per share for Q1 2026, reaffirming its dedication to shareholders and its leadership in biopharmaceuticals. The company focuses on innovation while navigating market challenges and maintaining sustainability.
November 18, 2025 Merck's WINREVAIR Shows Promise in Phase 2 CADENCE Study Merck's WINREVAIR has shown significant promise in the Phase 2 CADENCE study for treating combined post- and precapillary pulmonary hypertension. The study met its primary endpoint, indicating potential improvements in patient outcomes and paving the way for upcoming Phase 3 trials.
November 14, 2025 Merck & Co Inc. to Acquire Cidara Therapeutics: A Strategic Move in Antiviral Development Merck & Co Inc. has announced its acquisition of Cidara Therapeutics for approximately $9.2 billion, aiming to boost its antiviral pipeline with CD388, a drug designed to prevent influenza. The acquisition is expected to close in early 2026 and reflects Merck's commitment to addressing global health challenges.
November 13, 2025 Merck & Co. Inc. to Showcase Innovations at Jefferies Global Healthcare Conference Merck & Co. Inc. will participate in the Jefferies Global Healthcare Conference on November 20, 2025, featuring a fireside chat with key executives. The event aims to highlight Merck's innovations and commitment to improving global health. Stakeholders are invited to access the live webcast for insights into the company's strategic direction.
November 09, 2025 Merck's Enlicitide Decanoate Shows Promise in Reducing LDL-C for HeFH Patients Merck's enlicitide decanoate has shown a significant 59.4% reduction in LDL-C levels in HeFH patients, as revealed in the Phase 3 CORALreef trial. The treatment demonstrated a favorable safety profile and offers hope for improved management of this genetic disorder.
November 05, 2025 Merck & Co. Inc. Reports Strong Q3 2025 Results Amid Strategic Developments Merck & Co. Inc. reported strong Q3 2025 results with $17.3 billion in sales and a net income of $5.78 billion. The company is pursuing strategic acquisitions while facing challenges in pricing and tariffs. Despite these hurdles, Merck's diverse portfolio shows promise for continued growth.
November 04, 2025 Merck & Co Inc. Partners with Blackstone for Development of Sacituzumab Tirumotecan Merck & Co has partnered with Blackstone Life Sciences to secure $700 million for the development of sacituzumab tirumotecan (sac-TMT), targeting TROP2 in cancer cells. The funding aims to support ongoing clinical trials, particularly for treating triple-negative breast cancer, marking a significant step in cancer treatment advancements.
November 04, 2025 Merck & Co Inc. Announces Strategic Shift in Anti-CD30 Ligand Monoclonal Antibody Program Merck & Co Inc. has terminated its co-development agreement with Dr. Falk Pharma for the MK-8690 antibody, allowing its subsidiary to assume full control. The move involves a $150M upfront payment and reflects Merck's commitment to advancing its innovative therapies amid evolving financial landscapes.
October 30, 2025 Merck & Co., Inc. Reports Strong Third-Quarter 2025 Financial Results Merck & Co., Inc. announced strong Q3 2025 results, with sales reaching $17.276 billion and significant growth in key therapeutic areas. The company is committed to innovation, investing in R&D and manufacturing, and has updated its full-year financial outlook.
October 29, 2025 Merck and Eisai Announce Phase 3 LEAP-012 Trial Results for KEYTRUDA and LENVIMA in Liver Cancer The Phase 3 LEAP-012 trial by Merck and Eisai evaluated KEYTRUDA and LENVIMA for liver cancer treatment. Results showed significant progression-free survival but lacked overall survival benefit, leading to the study's closure. Ongoing research aims to improve therapeutic options for hepatocellular carcinoma.
October 29, 2025 Merck & Co. Secures European Commission Approval for KEYTRUDA® in Head and Neck Cancer Treatment Merck & Co. has received European Commission approval for KEYTRUDA® as the first anti-PD-1 therapy for advanced head and neck cancer. The treatment showed a 30% improvement in event-free survival compared to standard therapy, signifying a major advancement in oncology.
October 28, 2025 Merck & Co Inc. Reports Promising Results for KEYTRUDA and WELIREG in Kidney Cancer Merck & Co Inc. announced positive results from the LITESPARK-022 trial, showing that combining KEYTRUDA and WELIREG significantly improves disease-free survival for kidney cancer patients post-nephrectomy. The findings highlight new treatment possibilities for patients at high risk of recurrence.
October 28, 2025 Merck & Co. and Eisai Report Positive Results for WELIREG® and LENVIMA® in Advanced Renal Cell Carcinoma Merck & Co. and Eisai report that their combination therapy of WELIREG and LENVIMA significantly improves progression-free survival in advanced renal cell carcinoma patients. While overall survival showed positive trends, further analysis is pending. This trial underscores their commitment to innovative cancer treatments.
October 27, 2025 Merck & Co Inc. Receives FDA Approval for Updated Indication of WINREVAIR™ in PAH Treatment Merck & Co Inc. has received FDA approval for an updated indication of WINREVAIR in treating pulmonary arterial hypertension (PAH). The ZENITH study demonstrated a 76% reduction in major morbidity and mortality, marking a significant advancement in PAH therapy.
October 23, 2025 Merck & Co. Set to Unveil Groundbreaking Cardio-Pulmonary Research at AHA Scientific Sessions 2025 Merck & Co. will present its latest cardio-pulmonary research at the AHA Scientific Sessions 2025, highlighting pivotal Phase 3 trials for the PCSK9 inhibitor enlicitide. The findings promise to advance treatment for hypercholesterolemia and pulmonary arterial hypertension, addressing a critical global health burden.
October 23, 2025 Merck & Co. Inc. Announces FDA Priority Review for KEYTRUDA and KEYTRUDA QLEX in Bladder Cancer Treatment Merck's KEYTRUDA and KEYTRUDA QLEX have received FDA priority review for muscle-invasive bladder cancer treatment. This follows promising trial results showing significant improvements in survival rates for patients ineligible for chemotherapy. The target action date is set for April 2026.
October 21, 2025 Merck & Co. Presents Key Findings on Pneumococcal Disease and CAPVAXIVE® Vaccine Merck & Co. shared critical findings on pneumococcal disease and CAPVAXIVE® at IDWeek 2025. The vaccine shows superior efficacy against unique serotypes and addresses alarming antimicrobial resistance in adults.
October 20, 2025 Merck & Co Inc. Reports Groundbreaking Long-Term Survival Data for KEYTRUDA® in Non-Small Cell Lung Cancer Merck & Co Inc. announced groundbreaking long-term survival data for KEYTRUDA® in non-small cell lung cancer, highlighting its efficacy in extending survival. The results from pivotal trials demonstrate significant improvements in overall and event-free survival, marking a transformative advancement in cancer treatment.
October 20, 2025 Merck & Co. Inc. Announces Major Investment in U.S. Pharmaceutical Manufacturing Merck & Co. Inc. is investing $3 billion in a new pharmaceutical manufacturing facility in Elkton, Virginia, aiming to create over 500 jobs. This initiative is part of a broader strategy to strengthen U.S. biopharmaceutical manufacturing and innovation, reflecting Merck's commitment to enhancing healthcare and economic growth.
October 16, 2025 Merck & Co. Achieves Milestone in Ovarian Cancer Treatment with KEYNOTE-B96 Trial Results Merck & Co.'s KEYNOTE-B96 trial shows that KEYTRUDA combined with chemotherapy significantly improves overall survival for patients with platinum-resistant recurrent ovarian cancer. The trial's results mark a pivotal advancement in cancer treatment, emphasizing the need for innovative therapies in this challenging field.
October 15, 2025 Merck Unveils Phase 3 Trial Results for DOR/ISL: A Potential Game-Changer in HIV Treatment Merck's Phase 3 trials reveal that the DOR/ISL regimen for HIV-1 is effective and safe, showing no significant weight gain or adverse effects. As the FDA reviews this innovative treatment, it could revolutionize HIV management for many patients.
October 09, 2025 Merck to Showcase Groundbreaking HIV Research at EACS 2025 Merck will present pivotal HIV research at EACS 2025, highlighting new treatment options and prevention strategies. Their commitment to advancing HIV care is evident through various key presentations and symposiums planned at the conference.
October 09, 2025 Merck Advances Oncology Innovation at ESMO 2025: A Deep Dive into Their Latest Research Merck & Co Inc. will showcase over 100 abstracts at ESMO 2025, highlighting significant advancements in cancer research, particularly with KEYTRUDA. Key studies focus on bladder, ovarian, and lung cancers, emphasizing patient-centric innovations and strategic collaborations.
October 07, 2025 Merck & Co. Completes Strategic Acquisition of Verona Pharma On October 7, 2025, Merck & Co. announced its acquisition of Verona Pharma, which includes the innovative COPD treatment, Ohtuvayre. This strategic move aims to enhance Merck's respiratory disease portfolio and generate long-term growth, despite initial earnings impacts.
October 06, 2025 Merck & Co. Inc. Expands Tulisokibart Clinical Development Program Merck & Co. has announced an expansion of its clinical program for tulisokibart, launching three new Phase 2b trials for immune-mediated inflammatory diseases. The trials aim to recruit over 640 patients to assess the drug's efficacy in treating hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis.
October 01, 2025 Merck & Co. to Present Third-Quarter 2025 Results: Anticipation Builds Ahead of Earnings Call Merck & Co. is set to hold its third-quarter 2025 earnings call on October 30, providing key insights into its financial performance and strategic initiatives. The call will be accessible via webcast and phone, reflecting the company's commitment to innovation and community health amidst a dynamic pharmaceutical landscape.
September 30, 2025 Merck & Co. Inc. Announces Groundbreaking Results for WINREVAIR™ in Phase 3 HYPERION Trial Merck's Phase 3 HYPERION trial reveals WINREVAIR significantly reduces clinical worsening events in newly diagnosed pulmonary arterial hypertension patients. The promising results advocate for early intervention in treatment to improve patient outcomes.
August 05, 2025 Merck & Co., Inc. Reports Q2 2025 Results: Navigating a Complex Landscape Merck & Co., Inc. reported a 2% revenue decline in Q2 2025, attributing it to pricing pressures and market shifts. Despite challenges, the company remains focused on strategic acquisitions and innovation to enhance its market position.
May 15, 2025 Merck Reports Promising Results from Phase 3 KEYNOTE-B96 Trial for Ovarian Cancer Treatment Merck's Phase 3 KEYNOTE-B96 trial has shown promising results in improving progression-free and overall survival for patients with platinum-resistant ovarian cancer. This marks a significant advancement in treatment options, especially for those with PD-L1 expressing tumors. The study reinforces KEYTRUDA's efficacy in challenging cases.
May 14, 2025 FDA Approves Merck’s WELIREG®: A Milestone in Cancer Treatment for Rare Tumors The FDA has approved Merck's WELIREG® for adults and pediatric patients with advanced pheochromocytoma and paraganglioma, marking a significant innovation in cancer treatment. This new oral therapy offers a non-surgical option for patients previously facing limited alternatives.
May 13, 2025 Merck & Co Inc. Unveils Promising Oncology Developments Ahead of ASCO 2025 Merck & Co Inc. is set to present groundbreaking oncology research at ASCO 2025, showcasing new therapies and updates on established medicines. With a focus on addressing unmet medical needs, Merck aims to transform cancer treatment paradigms.
May 08, 2025 Merck & Co. Announces $895 Million Investment in Animal Health Manufacturing in Kansas Merck Animal Health is investing $895 million to expand its Kansas manufacturing facility, enhancing production and R&D capabilities. This project will create 2,500 jobs during construction and over 200 permanent positions, significantly impacting the local economy.
May 07, 2025 Merck & Co Inc. to Engage at Bank of America 2025 Global Healthcare Conference Merck & Co Inc. will participate in the Bank of America 2025 Global Healthcare Conference on May 14, 2025, featuring key executives discussing their strategic initiatives. The conference aims to provide insights into Merck's advancements in drug development, particularly in oncology, and their commitment to improving global health outcomes.
May 02, 2025 Merck & Co., Inc. Reports Q1 2025 Results: Navigating Challenges and Opportunities Merck & Co., Inc. reported Q1 2025 results, showcasing a 2% decline in revenue amid regulatory pressures. The company’s net income improved due to effective cost management, while strategic acquisitions aimed to bolster its market position.
April 29, 2025 Merck & Co Inc. Breaks Ground on $1 Billion Biologics Center in Delaware Merck & Co Inc. has begun construction on a $1 billion biologics center in Wilmington, Delaware, which aims to enhance its biologics capabilities and create thousands of jobs. This facility will serve as a key production site for the cancer therapy KEYTRUDA, underscoring Merck's commitment to U.S. manufacturing and innovation.
April 27, 2025 Merck & Co. Announces Landmark Results from KEYNOTE-689 Trial for KEYTRUDA® in Head and Neck Cancer Merck's KEYNOTE-689 trial demonstrated that KEYTRUDA significantly improves event-free survival in patients with advanced head and neck cancer. The promising results highlight the potential for integrating this immunotherapy with standard treatment protocols, representing a major advancement in cancer care.
April 24, 2025 Merck & Co. Reports Strong First Quarter 2025 Financial Results Merck & Co. reported strong financial results for Q1 2025, with a 7% increase in net income despite a 2% decline in sales. The oncology segment, driven by KEYTRUDA, showed significant growth while the company maintains a positive outlook for the full year.
April 14, 2025 Merck & Co., Inc. Faces Securities Fraud Class Action Lawsuit Merck & Co., Inc. is facing a class action lawsuit for allegedly violating securities laws by making misleading statements about its HPV vaccine, Gardasil. Investors from February 2022 to February 2025 are encouraged to participate in the suit to recover losses. The Schall Law Firm is actively seeking affected shareholders and offering consultations.
April 14, 2025 Merck & Co. Faces Legal Scrutiny: Investors Urged to Act Merck & Co. is under investigation for allegedly making misleading statements regarding its Gardasil vaccine revenue projections. A federal class action has been filed, urging investors to act before the April 2025 deadline. The situation has caused significant stock declines, prompting a call to action for affected shareholders.
April 11, 2025 Merck & Co. Faces Class Action Lawsuit Over Securities Fraud Allegations Merck & Co. is facing a class action lawsuit due to securities fraud allegations related to its Gardasil vaccine. Investors are urged to act before the April 14, 2025 deadline as the company struggles with significant operational challenges impacting its stock value.
April 01, 2025 Merck & Co Inc. Announces Q1 2025 Sales and Earnings Conference Call Merck & Co Inc. will hold a conference call on April 24, 2025, to discuss its Q1 sales and earnings. Investors can expect insights on the company's performance and future strategies in the evolving pharmaceutical landscape.
March 31, 2025 Merck & Co. Inc. Reports Groundbreaking Results for WINREVAIR™ in Phase 3 ZENITH Trial Merck's WINREVAIR™ demonstrated a 76% decrease in major morbidity and mortality events in the Phase 3 ZENITH trial for pulmonary arterial hypertension. The trial's results, presented at ACC.25, indicate a significant advancement in PAH treatment, with plans for global regulatory submissions ahead.
March 27, 2025 Merck's Breakthrough: Subcutaneous Pembrolizumab Shows Promise in Lung Cancer Treatment Merck's investigational subcutaneous pembrolizumab shows promise in lung cancer treatment, achieving effective results in the 3475A-D77 trial compared to IV KEYTRUDA. The FDA is reviewing its application for approval, potentially transforming patient care.
March 26, 2025 Merck's CAPVAXIVE® Vaccine Receives European Commission Approval: A New Hope Against Pneumococcal Disease Merck's CAPVAXIVE vaccine has been approved by the European Commission to prevent invasive pneumococcal disease in adults. With broader serotype coverage than existing vaccines, it promises to enhance public health outcomes for vulnerable populations, especially those over 65 and with chronic conditions.
March 25, 2025 Merck & Co. Enters Exclusive License Agreement for Innovative Cardiovascular Treatment Merck & Co. has entered an exclusive agreement with Jiangsu Hengrui Pharmaceuticals to develop HRS-5346, an oral treatment for elevated lipoprotein(a), a major cardiovascular risk factor. The deal includes a $200 million upfront payment and potential milestone payments totaling $1.77 billion, reflecting Merck's commitment to expanding its cardio-metabolic pipeline.
March 12, 2025 Merck & Co. Inc. Announces Promising Phase 3 Trial Results for HIV Treatment Merck & Co. Inc. has announced promising results from Phase 3 trials of its HIV treatment DOR/ISL, which maintained high viral suppression rates. The trials demonstrated non-inferiority compared to existing regimens, with a safety profile comparable to current therapies. Regulatory submissions are planned for mid-2025.
March 11, 2025 Merck & Co Inc. Expands Vaccine Production with New $1 Billion Facility Merck & Co Inc. has opened a $1 billion vaccine manufacturing facility in Durham, NC, as part of a larger investment strategy to enhance U.S. production capabilities. The state-of-the-art plant features advanced technologies and aims to improve vaccine accessibility while creating jobs and fostering community growth.
February 28, 2025 Merck & Co Inc. Faces Securities Fraud Lawsuit Amidst Gardasil Sales Decline Merck & Co Inc. is facing a class action lawsuit following a decline in Gardasil sales and stock price. Allegations include securities fraud and misleading statements about business prospects, particularly in China. Investors are urged to file motions by April 14, 2025.
February 27, 2025 Merck & Co Inc. Faces Legal Challenge Amid Gardasil Sales Decline Merck & Co Inc. is facing a class action lawsuit due to significant losses linked to a decline in Gardasil sales, particularly in China. Investors are urged to file motions before the April 14, 2025, deadline as the company grapples with allegations of misleading statements about its future prospects.
February 25, 2025 Merck & Co., Inc. 2024 Annual Report: A Year of Growth and Challenges Merck & Co., Inc. reported a 7% revenue growth in 2024, reaching $64.2 billion, driven by strong sales in oncology and animal health. Despite facing pricing pressures and regulatory scrutiny, the company remains focused on innovation and strategic investments to ensure future growth.
February 25, 2025 Merck & Co., Inc. Faces Class Action Lawsuit Amidst Investor Concerns Merck & Co., Inc. is facing a class action lawsuit for alleged violations of federal securities laws, primarily concerning misleading revenue projections related to Gardasil. Investors who purchased Merck securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the lawsuit, which operates on a contingency fee basis for legal representation.
February 25, 2025 Merck & Co Faces Class Action Lawsuit Over Alleged Securities Fraud Merck & Co Inc. is under a class action lawsuit for allegedly misleading investors about its Gardasil vaccine sales. Following significant inventory issues and stock price declines, affected investors have until April 14, 2025, to file claims.
February 25, 2025 Merck & Co Inc. Announces FDA Priority Review for KEYTRUDA®: A New Hope for Head and Neck Cancer Patients Merck's KEYTRUDA® has been submitted for FDA priority review to treat locally advanced head and neck cancer, potentially improving patient outcomes. The application is based on positive results from the KEYNOTE-689 trial, and a decision is expected by June 2025.
February 24, 2025 Merck & Co Faces Legal Challenges Amid Gardasil Sales Decline Merck & Co is embroiled in a securities fraud class action lawsuit following a sharp drop in Gardasil sales, attributed to misleading statements about demand. Investors are urged to take action before the April 2025 deadline for filing claims.
February 24, 2025 Merck & Co Inc. Set to Engage Investors at TD Cowen 45th Annual Health Care Conference Merck & Co Inc. will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, featuring key executives discussing the company's strategies. The event aims to foster transparency and showcase Merck's commitment to innovation and diversity in healthcare.
February 21, 2025 Merck & Co Inc. Faces Class Action Lawsuit Amid Gardasil Sales Decline Merck & Co Inc. is under a class action lawsuit from investors amid falling stock prices linked to poor Gardasil sales in China. The lawsuit claims securities fraud due to misleading statements by the company. Investors are encouraged to join the lawsuit by the April 14, 2025 deadline.
February 20, 2025 Merck & Co Faces Securities Fraud Investigation Amid Gardasil Sales Concerns Merck & Co is facing a securities fraud investigation due to a significant drop in Gardasil vaccine sales, leading to major stock declines and revised financial projections. Investors are encouraged to seek legal recourse as the company navigates this challenging situation.
February 20, 2025 Investors Alert: Merck & Co Faces Securities Fraud Investigation Amid Gardasil Shipment Issues Merck & Co is facing a securities fraud investigation after significant declines in Gardasil vaccine shipments to China led to stock price drops. Investors are encouraged to explore potential recovery claims due to their financial losses.
February 19, 2025 Securities Fraud Investigation Launched into Merck & Co. Amid Gardasil Sales Decline Merck & Co. is facing a securities fraud investigation due to significant declines in Gardasil sales, leading to a substantial drop in stock prices. The inquiry aims to determine if the company misled investors regarding its financial outlook and product demand. Affected investors are encouraged to explore legal options.
February 18, 2025 Merck & Co. Secures Conditional Approval for WELIREG® in Europe Merck's WELIREG® has received conditional approval from the EU for treating VHL disease-associated tumors and advanced clear cell RCC. This first-in-class HIF-2α inhibitor demonstrates promising efficacy and expands treatment options for patients with limited therapies available.
February 17, 2025 Merck & Co., Inc. Faces Class Action Lawsuit Amid Allegations of Securities Fraud Merck & Co., Inc. faces a class action lawsuit alleging securities fraud related to misleading statements about its HPV vaccine, Gardasil. Investors are encouraged to join the lawsuit, with no upfront costs involved. The outcome may significantly impact Merck's stock and reputation.
February 15, 2025 Merck & Co., Inc. Faces Class Action Lawsuit Over Securities Fraud Allegations Merck & Co., Inc. has been hit by a class action lawsuit alleging securities fraud related to misleading statements about its HPV vaccine, Gardasil. The lawsuit claims Merck inflated product demand and concealed critical information, affecting investor confidence. Shareholders are encouraged to join the lawsuit by April 14, 2025, to seek potential compensation.
February 14, 2025 Merck & Co. Faces Class Action Lawsuit Amidst Declining Sales and Allegations of Misleading Statements Merck & Co. is facing a class action lawsuit due to allegations of misleading investors about its financial health and declining Gardasil vaccine sales. The lawsuit, initiated by Robbins Geller, highlights significant financial losses for shareholders. Investors are encouraged to join the action before the April 2025 deadline.
February 13, 2025 Merck & Co., Inc. Faces Class Action Lawsuit: Shareholders Urged to Act Merck & Co., Inc. is facing a class action lawsuit due to allegations of misleading investors regarding Gardasil's sales projections. Shareholders who suffered losses over $100,000 are encouraged to act, with the Rosen Law Firm leading the case. The outcome could significantly impact investor perceptions and the company's future.
February 12, 2025 Merck & Co. Inc. Faces Securities Class Action Investigation Amidst Financial Concerns Merck & Co. Inc. is facing a securities class action investigation following a significant stock decline due to disappointing financial disclosures. The Rosen Law Firm is preparing to represent affected shareholders seeking compensation for their losses.
February 06, 2025 SWOT Analysis of Merck & Co Inc. in 2025 This SWOT analysis of Merck & Co Inc. in 2025 reviews its strengths, including a strong pharmaceutical portfolio and significant R&D investment, while addressing weaknesses like dependency on key products. It also discusses opportunities for growth in emerging markets and threats from competition and regulatory changes.
February 06, 2025 Merck & Co Inc. Launches Pivotal Phase 3 Trial for Zilovertamab Vedotin in DLBCL Treatment Merck & Co has launched the waveLINE-010 Phase 3 trial to evaluate zilovertamab vedotin for untreated diffuse large B-cell lymphoma. The study aims to compare its efficacy with the current standard treatment, R-CHOP, focusing on progression-free survival and overall patient outcomes.
November 06, 2024 Merck & Co. Inc. Reports Strong Q3 2024 Results Amid Strategic Acquisitions and Market Challenges Merck & Co. reported strong Q3 2024 results with $16.65 billion in sales, propelled by its oncology segment and strategic acquisitions. Despite a decline in net income due to rising expenses, the company's aggressive growth strategy and innovation focus position it well for the future.
August 05, 2024 Merck & Co. Inc. Reports Strong Q2 2024 Financial Results Amid Strategic Acquisitions Merck & Co. Inc. reported strong financial results in Q2 2024, with $16.1 billion in sales and significant net income growth. Strategic acquisitions in animal health and ophthalmology further bolster its portfolio as the company aims for continued expansion.
May 03, 2024 Merck & Co. Inc. Reports Strong Q1 2024 Results Amid Strategic Acquisitions Merck & Co., Inc. demonstrated strong financial results in Q1 2024, with $15.8 billion in sales, a 9% increase from 2023. The company continues to expand through strategic acquisitions in oncology and animal health, bolstering its market position.
